Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Intuit Inc. (INTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Intuit Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223 (market cap $29.97B), while Intuit Inc. trades at $336.53 (market cap $91.56B). The key difference: Intuit Inc. is far larger — about 3.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Intuit Inc. pays a 1.43% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | INTU | |
|---|---|---|
Market Cap | $29.97B | $91.56B |
Sector | Health | Technology |
52-Week High | $491.22 | $717.21 |
52-Week Low | $205.48 | $255.07 |
Enterprise Value | $27.93B | $90.01B |
Dividend Yield | — | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Intuit (INTU) trades at $336.44, up 0.6% today, with a bullish technical signal from moving averages and oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $12.8 exceeding expectations. Revenue grew to $18.83B in 2025, with a net income margin of 21.91%. However, the stock faces headwinds from multiple law firm investigations into securities fraud allegations related to pricing issues, contributing to a 20% stock drop recently noted by Forbes on June 2, 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $402.26 suggest upside, but legal risks and overbought RSI levels near 81.6 pose near-term challenges. Investors should weigh the company's AI-driven growth in financial software against regulatory scrutiny and competitive pressures in the fintech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
